Literature DB >> 2684681

Oral iron chelators: prospects for future development.

J Porter1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2684681     DOI： 10.1111/j.1600-0609.1989.tb00300.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN： 0902-4441            Impact factor:   2.997


× No keyword cloud information.
  4 in total

1.  Rare occurrence of DNMT3A mutations in myelodysplastic syndromes.

Authors:  Felicitas Thol; Claudia Winschel; Andrea Lüdeking; Haiyang Yun; Inna Friesen; Frederik Damm; Katharina Wagner; Jürgen Krauter; Michael Heuser; Arnold Ganser
Journal:  Haematologica       Date:  2011-08-31       Impact factor: 9.941

2.  Pharmaceutical analysis of the oral iron chelator deferiprone (DMHP,L1).

Authors:  R Lange; W Lameijer; C Slijkhuis; D de Kaste
Journal:  Pharm World Sci       Date:  1996-08

3.  IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis.

Authors:  Felicitas Thol; Eva M Weissinger; Jürgen Krauter; Katharina Wagner; Frederik Damm; Martin Wichmann; Gudrun Göhring; Christiane Schumann; Gesine Bug; Oliver Ottmann; Wolf-Karsten Hofmann; Brigitte Schlegelberger; Arnold Ganser; Michael Heuser
Journal:  Haematologica       Date:  2010-05-21       Impact factor: 9.941

4.  Efficacy and safety of deferiprone (Ferriprox), an oral iron-chelating agent, in pediatric patients.

Authors:  Sung Chul Won; Dong Kyun Han; Jong Jin Seo; Nak Gyun Chung; Sang Kyu Park; Kyung Bae Park; Hoon Kook; Chuhl Joo Lyu
Journal:  Korean J Hematol       Date:  2010-03-31
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.